Abstract
Hepatitis B reactivation due to chemotherapy is a cause of serious morbidity and mortality in some of the patients with cancer. In this study, we retrospectively assessed the prevalence of hepatitis B reactivation among the patients undergoing cytotoxic chemotherapy. We investigated efficacy of lamivudine prophylaxis against hepatitis B reactivation as well.
MeSH terms
-
Anti-HIV Agents / therapeutic use
-
Antineoplastic Agents / adverse effects*
-
Female
-
Hepatitis B / drug therapy
-
Hepatitis B / metabolism
-
Hepatitis B / prevention & control*
-
Hepatitis B Surface Antigens / metabolism*
-
Hepatitis B virus / drug effects
-
Hepatitis B virus / growth & development*
-
Humans
-
Lamivudine / therapeutic use
-
Male
-
Neoplasms / drug therapy
-
Neoplasms / metabolism
-
Neoplasms / virology*
-
Retrospective Studies
-
Treatment Outcome
-
Virus Activation / drug effects*
Substances
-
Anti-HIV Agents
-
Antineoplastic Agents
-
Hepatitis B Surface Antigens
-
Lamivudine